Hair and nail manifestations of COVID-19.
hair
hair disease
hair disorders
hairloss
infection
nail disorders
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
12
11
2021
received:
16
06
2021
accepted:
10
01
2022
pubmed:
16
1
2022
medline:
6
4
2022
entrez:
15
1
2022
Statut:
ppublish
Résumé
Emerging literature evidence shows that the manifestations of the coronavirus disease 2019 (COVID-19), which is the disease caused by SARS-CoV-2, encompass alterations of the pulmonary, cardiovascular, gastrointestinal, and neurological system. Moreover, hematologic and dermatologic manifestations have been documented. The aim of this review is to summarize the dermatologic manifestations of COVID-19 involving the hair and nails in a narrative way. A total of 1136 patients have been reported to have de novo hair loss following COVID-19. Notably, 958 patients experienced telogen effluvium (TE) (female/male ratio = 3,86:1), two female patients experienced anagen effluvium, and 176 people had alopecia areata (female/male ratio of 19:3). Ten patients were reported to have ungual changes following the infection with the novel coronavirus: The individuals affected were 6 women and 4 men. COVID-19 can be associated with hair and ungual manifestations. This review summarizes the evidence regarding the hair and ungual manifestations of COVID-19, which could be harnessed to better understand the clinical implications and pathophysiology of this disease that has been burdening society globally since December 2019.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1339-1346Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Wang C, Wang Z, Wang G, Lau JYN, Zhang K, Li W. COVID-19 in early 2021: current status and looking forward. Signal Transduct Target Ther. 2021;6(1):1-14. doi:10.1038/s41392-021-00527-1.
Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med. Published online March 24, 2021;384(19):1866-1868. doi:10.1056/NEJMc2100362
Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-1032. doi:10.1038/s41591-020-0968-3.
Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol JEADV. Published online April 24, 2020;34(7). doi:10.1111/jdv.16530
Tammaro A, Adebanjo GAR, Chello C, et al. Severe palmar hyperkeratosis and hematochezia in COVID-19. Dermatol Ther. Published online October 18, 2020:e14423. doi:10.1111/dth.14423
Fernandez-Nieto D, Jimenez-Cauhe J, Ortega-Quijano D, Diaz-Guimaraens B, Dominguez-Santas M, Martinez-Rubio J. Transverse leukonychia (Mees’ lines) nail alterations in a COVID-19 patient. Dermatol Ther. Published online June 17, 2020:e13863. doi:10.1111/dth.13863
Domínguez-Santás M, Haya-Martínez L, Fernández-Nieto D, Jiménez-Cauhé J, Suárez-Valle A, Díaz-Guimaraens B. Acute telogen effluvium associated with SARS-CoV-2 infection. Aust J Gen Pract. 2020;49: doi:10.31128/AJGP-COVID-32.
Rossi A, Magri F, Michelini S, et al. New onset of alopecia areata in a patient with SARS-CoV-2 infection: Possible pathogenetic correlations? J Cosmet Dermatol. Published online March 19, 2021. doi:10.1111/jocd.14080
Capalbo A, Giordano D, Gagliostro N, et al. Alopecia areata in a COVID-19 patient: A case report. Dermatol Ther. 2021;34(2):e14685. doi:10.1111/dth.14685.
Miyazato Y, Morioka S, Tsuzuki S, et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum Infect Dis. Published online October 21, 2020. doi:10.1093/ofid/ofaa507
FIvenson D. COVID-19: association with rapidly progressive forms of alopecia areata. Int J Dermatol. 2021;60(1):127. doi:10.1111/ijd.15317
Sgubbi P, Savoia F, Calderoni O, Longo R, Stinchi C, Tabanelli M. Alopecia areata in a patient with SARS-Cov-2 infection. Dermatol Ther. Published online September 10, 2020:e14295. doi:10.1111/dth.14295
Galadari I, Marzooqi AA, Naeem AA, Ali S, Adawi M, Galadari H. Cutaneous Manifestations of COVID-19: A Report from the United Arab Emirates. Skinmed. 2020;18(4):218-220.
Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89-95. doi:10.1016/j.cmi.2020.09.023.
Olds H, Liu J, Luk K, Lim HW, Ozog D, Rambhatla PV. Telogen effluvium associated with COVID-19 infection. Dermatol Ther. Published online January 6, 2021:e14761. doi:10.1111/dth.14761
Almeida G, Arruda S, Marques E, Michalany N, Sadick N. Presentation and Management of Cutaneous Manifestations of COVID-19. J Drugs Dermatol JDD. 2021;20(1):76-83. doi:10.36849/JDD.5676.
Hayran Y, Yorulmaz A, Gür G, Aktaş A. Different hair loss patterns in two pediatric patients with COVID-19-associated multisystem inflammatory syndrome in children. Dermatol Ther. 2021;34(2):e14820. doi:10.1111/dth.14820.
Trüeb RM, Dutra Rezende H, Gavazzoni Dias MFR. What can the hair tell us about COVID-19? Exp Dermatol. Published online December 14, 2020. doi:10.1111/exd.14259
Mieczkowska K, Deutsch A, Borok J, et al. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021;60(1):122-124. doi:10.1111/ijd.15313.
Moreno-Arrones OM, Lobato-Berezo A, Gomez-Zubiaur A, et al. SARS-CoV-2-induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol JEADV. 2021;35(3):e181-e183. doi:10.1111/jdv.17045.
Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. Published online November 23, 2020. doi:10.1111/dth.14547
Di Landro A, Naldi L, Glaser E, Paus R, Tosti A. Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients. Exp Dermatol. Published online April 10, 2021. doi:10.1111/exd.14352
Cline A, Jacobs AK, Fonseca M, et al. Race, ethnicity, and comorbidities are critical factors in the diagnosis of telogen effluvium during the COVID-19 pandemic. J Am Acad Dermatol. Published online April 8, 2021. doi:10.1016/j.jaad.2021.03.099
Lv S, Wang L, Zou X, et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection. Clin Cosmet Investig Dermatol. 2021;14:385-387. doi:10.2147/CCID.S307982.
Rossi A, Magri F, Sernicola A, et al. Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms. Skin Appendage Disord. 2021;7(5):377-381. doi:10.1159/000517223.
Deng J, Ngo T, Zhu TH, Halverstam C. Telogen effluvium, Beau lines, and acral peeling associated with COVID-19 infection. JAAD Case Rep. 2021;13:138-140. doi:10.1016/j.jdcr.2021.05.026.
Starace M, Iorizzo M, Sechi A, et al. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021;5:11-18. doi:10.1016/j.jdin.2021.07.006.
Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Ir J Med Sci. Published online August 31, 2021:1-5. doi:10.1007/s11845-021-02754-5
Babaei K, Kavoussi H, Rezaei M, Kavoussi R. Characteristics of telogen effluvium in COVID-19 in western Iran (2020). An Bras Dermatol. Published online September 15, 2021. doi:10.1016/j.abd.2021.05.006
Vastarella M, Cantelli M, Nappa P, Fabbrocini G, Ocampo-Garza SS. Black dots in trichoscopy after COVID-19. Can it be telogen effluvium? Dermatol Ther. 2021;34(5):e15053.;. doi:10.1111/dth.15053.
Abrantes TF, Artounian KA, Falsey R, et al. Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad Dermatol. 2021;85(4):975-976. doi:10.1016/j.jaad.2021.07.021.
Berbert Ferreira S, Gavazzoni Dias MFR, Berbert Ferreira R, Neves Neto AC, Trüeb RM, Lupi O. Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib. J Eur Acad Dermatol Venereol JEADV. Published online February 15, 2021. doi:10.1111/jdv.17170
Shanshal M. COVID-19 related anagen effluvium. J Dermatol Treat. Published online July 16, 2020:1-2. doi:10.1080/09546634.2020.1792400
Neri I, Guglielmo A, Virdi A, Gaspari V, Starace M, Piraccini BM. The red half-moon nail sign: a novel manifestation of coronavirus infection. J Eur Acad Dermatol Venereol. Published online June 29, 2020. doi:10.1111/jdv.16747
Tammaro A, Adebanjo GAR, Erasmus H, et al. Transverse orange nail lesions following SARS-CoV-2 infection. Dermatol Ther. 2021;34(1): doi:10.1111/dth.14688.
Méndez-Flores S, Zaladonis A, Valdes-Rodriguez R. COVID-19 and nail manifestation: be on the lookout for the red half-moon nail sign. Int J Dermatol. 2020;59(11):1414. doi:10.1111/ijd.15167.
Alobaida S, Lam JM. Beau lines associated with COVID-19. CMAJ can Med Assoc J. 2020;192(36):E1040. doi:10.1503/cmaj.201619.
Ide S, Morioka S, Inada M, Ohmagari N. Beau’s Lines and Leukonychia in a COVID-19 Patient. Intern Med Tokyo Jpn. 2020;59(24):3259. doi:10.2169/internalmedicine.6112-20.
Senturk N, Ozdemir H. Onychomadesis following COVID-19 infection: Is there a relationship? Dermatol Ther. 2020;33(6):e14309. doi:10.1111/dth.14309.
Demir B, Yuksel EI, Cicek D, Turkoglu S. Heterogeneous red-white discoloration of the nail bed and distal onycholysis in a patient with COVID-19. J Eur Acad Dermatol Venereol. Published online May 28, 2021:10.1111/jdv.17347. doi:10.1111/jdv.17347
Ceccarelli MA, Nakamura RC, Canella C. Multiple retronychia following COVID-19 infection. Vis J Emerg Med. 2021;24: doi:10.1016/j.visj.2021.101087. 101087.
Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347-369. doi:10.1016/j.yfrne.2014.04.004.
Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. J Autoimmun. 2019;98:74-85. doi:10.1016/j.jaut.2018.12.001.
Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”. J Am Acad Dermatol. 2020;83(2):680-682. doi:10.1016/j.jaad.2020.05.079.
Goren A, Vaño-Galván S, Wambier CG, et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. Published online April 16, 2020. doi:10.1111/jocd.13443
Mulinari-Brenner F. Psychosomatic aspects of alopecia areata. Clin Dermatol. 2018;36(6):709-713. doi:10.1016/j.clindermatol.2018.08.011.
Gentile P, Alves R, Cole JP, et al. AIRMESS - Academy of International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic alopecia and wound healing. Expert Opin Biol Ther. Published online April 5, 2021:1-7. doi:10.1080/14712598.2021.1908995
Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther. 2020;20(7):711-716. doi:10.1080/14712598.2020.1761322.
Gentile P, Sterodimas A, Pizzicannella J, Calabrese C, Garcovich S. Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), Drugs, and Vaccines in Inhibiting COVID-19 Disease. Aging Dis. 2020;11(5):1191-1201. doi:10.14336/AD.2020.0711.
Gentile P. The new regenerative and innovative strategies in hair loss. EClinicalMedicine. 2021;37: doi:10.1016/j.eclinm.2021.100995.100995.
Zhou S, Qi F, Gong Y, et al. Platelet-Rich Plasma in Female Androgenic Alopecia: A Comprehensive Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12: doi:10.3389/fphar.2021.642980.
Saleh D, Nassereddin A, Cook C. Anagen Effluvium. In: StatPearls. StatPearls Publishing; 2021. Accessed April 8, 2021. http://www.ncbi.nlm.nih.gov/books/NBK482293/
Hughes EC, Saleh D. Telogen Effluvium. In: StatPearls. StatPearls Publishing; 2021. Accessed February 27, 2021. http://www.ncbi.nlm.nih.gov/books/NBK430848/
Jamal M, Bangash HI, Habiba M, et al. Immune dysregulation and system pathology in COVID-19. Virulence. 2021;12(1):918-936. doi:10.1080/21505594.2021.1898790.
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-724. doi:10.1126/science.abc6027.
Frumholtz L, Bouaziz JD, Battistella M, et al. Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak. Br J Dermatol. n/a(n/a). doi:10.1111/bjd.20707
Żeberkiewicz M, Rudnicka L, Malejczyk J. Immunology of alopecia areata. Cent-Eur J Immunol. 2020;45(3):325-333. doi:10.5114/ceji.2020.101264.
Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. Published online October 28, 2021. doi:10.1172/JCI154886
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4): doi:10.1016/j.autrev.2021.102792. 102792.
Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19(8): doi:10.1016/j.autrev.2020.102597.
Singal A, Arora R. Nail as a window of systemic diseases. Indian Dermatol Online J. 2015;6(2):67-74. doi:10.4103/2229-5178.153002.